

CURRICULUM VITAE



INFORMAZIONI PERSONALI

CICCONE, LUCIA PIA
Indirizzo STRADA PRIVATA CAMPEGGI, 53 27100 PAVIA (PV) ITALY
Telefono +39 0382078501
E-mail lucia.ciccone@cnao.it - direzionemedica@cnao.it
Nazionalità Italiana
Data di nascita 28/09/1989

ESPERIENZA LAVORATIVA

Dal 17/01/2022 - attuale
Fondazione CNAO (Centro Nazionale di Adroterapia Oncologica)
Strada Privata Campeggi, 53 27100 Pavia (PV) Italy
Dipartimento clinico – Unità di neuro-oncologia

EDUCAZIONE E FORMAZIONE

29/12/2017-29/12/2021
AOU Careggi - DSBSC "Mario Serio", Università di Firenze, Firenze (Italia)
Unità di Radioterapia Oncologica
Medico in formazione specialistica in Radioterapia Oncologica

26/07/2017 - attuale
Iscrizione all'Ordine dei Medici Chirurghi e degli Odontoiatri di Foggia

2017/1
Abilitazione all'esercizio della professione medica
Università di Firenze, Firenze (Italia)

2008 - 2017
Laurea Magistrale in medicina e Chirurgia
Università di Firenze, Firenze (Italia)

2003 - 2008
Diploma di maturità scientifico-tecnologico
Liceo statale "Maria Immacolata" indirizzo scientifico-tecnologico
San Giovanni Rotondo, Foggia, Italy

ATTIVITA' DI RICERCA

17/01/2022 - attuale
Fondazione CNAO
Clinical trial Co-investigator: AIRC IG 2020 – n. 24946

29/12/2017-29/12/2021

AOU Careggi - DSBSC "Mario Serio" Università di Firenze, Firenze (Italia)

Unità di Radioterapia Oncologica

Clinical trial Co-investigator: ADAURA, SAVANNAH, IMREAL, NEMO, REACTION, PACIFIC R, PACIFIC 4, BE PACIFIC, MK7902-007, MK 7339-012, MK 7339-013, MP-LALC, KEYNOTE 189, KEYNOTE 867, TRENDS, AMG 510 2019009, AMG 510 20190294, DUART, CORELAB, ZEAL-1, COSTAR lung, OVIDIO, SKELETON, BACHNET, REGOMA-OSS, EORTC-1635 (IWOT), ARTO, PRIMERA, COMPLEEMENT-1, SAFE trial, OLIGOCARE.

**ABILITA' PERSONALI
E COMPETENZE**

MADRELINGUA

ITALIANA

ALTRE LINGUE

INGLESE

- Abilità di lettura
- Abilità di scrittura
- Abilità di comunicazione verbale

Eccellente

Eccellente

Buono

**ABILITA' ORGANIZZATIVE
E COMPETENZE**

MANAGEMENT DI PAZIENTI CON PATOLOGIA ONCOLOGICA ALL'INTERNO DI TEAM MULTIDISCIPLINARI
STESURA DI PROGETTI DI RICERCA
CONDUZIONE DI TRIAL CLINICI

**ABILITA' TECNICHE
E COMPETENZE**

PACCHETTO OFFICE
RICERCHE IN DATABASE PUBBLICI
SOFTWARE DI BIO-STATISTICA (SPSS, MedCalc)

ALLEGATI

ALLEGATO 1: ATTIVITA' DI PEER REVIEW
ALLEGATO 2: LISTA DI PUBBLICAZIONI SCIENTIFICHE
ALLEGATO 3: AFFILIAZIONI A SOCIETA' SCIENTIFICHE

ALLEGATO 1: ATTIVITA' DI PEER REVIEW

October 2020 - ATTUALE

Critical Reviews in Oncology/Hematology (ISSN: 1040-8428)

American Journal of Clinical Oncology (ISSN: 0277-3732)

La Radiologia Medica (ISSN: 1826-6983)

Urologic Oncology: Seminars and Original Investigations (ISSN: 1078-1439)

ALLEGATO 2: LISTA DI PUBBLICAZIONI SCIENTIFICHE

Orcid ID: <https://orcid.org/0000-0002-7657-7020>

Altro IDs Scopus Author ID: 57205152537

H-Index (secondo SCOPUS) = 6

Documenti per autore = 21

Numero totale di citazioni = 142

1. 1041P Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial
Camerini A, Mazzoni F, Scotti V, Tibaldi C, Sbrana A, Calabrò L, Caliman E, **Ciccione LP**, Grosso MA, Chella A, Amoroso D, Baldini E.
Annals of Oncology Vol. 33 Supplement S1031 Published in issue: September 2022 doi: 10.1016/j.annonc.2022.07.1167
[https://www.annalsofncology.org/article/S0923-7534\(22\)03018-6/fulltext](https://www.annalsofncology.org/article/S0923-7534(22)03018-6/fulltext)
2. Tumor-Associated Macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer.
Loi M, Salvatore G, Sottili M, Calosi L, Desideri I, Becherini C, Salvestrini V, **Ciccione LP**, Stocchi G, Meattini I, Francolini G, Mangoni M, Livi L.
Clin Transl Oncol. 2022 Jul;24(7):1395-1402. doi: 10.1007/s12094-022-02785-z.
<https://link.springer.com/article/10.1007/s12094-022-02785-z>
3. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
Francolini G, Detti B, Di Cataldo V, Garlatti P, Aquilano M, Allegra A, Lucidi S, Cerbai C, **Ciccione LP**, Salvestrini V, Stocchi G, Guerrieri B, Visani L, Loi M, Desideri I, Mangoni M, Meattini I, Livi L.
Radiol Med. 2022 Aug;127(8):912-918. doi: 10.1007/s11547-022-01511
<https://link.springer.com/article/10.1007/s11547-022-01511-7>
4. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)
Francolini G, Loi M, **Ciccione LP**, Detti B, Di Cataldo V, Pinzani P, Salvianti F, Salvatore G, Sottili M, Santini C, Frosini G, Visani L, Burchini L, Mattioli C, Allegra AG, Valzano M, Cerbai C, Aquilano M, Salvestrini V, Desideri I, Mangoni M, Meattini I, Livi L.
Med Oncol. 2022 Jun 10;39(8):119. doi: 10.1007/s12032-022-01756-2.
<https://link.springer.com/article/10.1007/s12032-022-01756-2>
5. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833).
Desideri I, Lucidi S, Francolini G, Meattini I, **Ciccione LP**, Salvestrini V, Valzano M, Morelli I, Angelini L, Scotti V, Bonomo P, Greto D, Terziani F, Becherini C, Visani L, Livi L.
Med Oncol. 2022 Jun 6;39(8):113. doi: 10.1007/s12032-022-01723-x.
<https://link.springer.com/article/10.1007/s12032-022-01723-x>
6. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterone in mCPRC: ARTO trial NCT03449719
Francolini G, Detti B, Di Cataldo V, Caini S, Alitto AR, Parisi S, Demofonti C, Bruni A, Ingresso G, Timon G, Tagliagambe A, Aquilano M, **Ciccione LP**, Salvestrini V, Frosini G, Cerbai C, Allegra A, Burchini L, Desideri I, Mangoni M, Meattini I, Livi L.
Radiotherapy and Oncology, Vol 170, Suppl 1, S530-S531, May 01, 2022. doi: 10.1016/S0167-8140(22)02627-5
[https://www.thegreenjournal.com/article/S0167-8140\(22\)02627-5/fulltext#relatedArticles](https://www.thegreenjournal.com/article/S0167-8140(22)02627-5/fulltext#relatedArticles)

7. PD-0411 Predictive factors of late GU toxicity after Cyberknife re-irradiation for locally recurrent PCA
 Francolini G, Cerbai C, Loi M, Di Cataldo V, Detti B, Simontacchi G, **Cicccone LP**, Masi L, Doro R, Allegra A, Salvestrini V, Mattioli C, Frosini G, Burchini L, Aquilano M, Stocchi G, Desideri I, Livi L.
 Radiotherapy and Oncology, Vol 170, Suppl 1, S354, May 01, 2022. doi: 10.1016/S0167-8140(22)02846-8
[https://www.thegreenjournal.com/article/S0167-8140\(22\)02846-8/fulltext](https://www.thegreenjournal.com/article/S0167-8140(22)02846-8/fulltext)

8. PO-1324 Accelerated hypofractionation with SIB-IMRT in Anal Cancer: assessment of efficacy and toxicity
 Lucidi S, Bertini N, Loi M, Bonomo P, Francolini G, Greto D, Simontacchi G, Galardi A, Marrazzo L, Allegra A, Guerrieri B, Scoccimarro E, Mariotti M, Carnevale MG, Stocchi G, **Cicccone LP**, Peruzzi A, Lorenzetti V, Talamonti C, Pallotta S, Mangoni M, Livi L.
 Radiotherapy and Oncology, Vol 170, Suppl 1, S1118-S1120, May 01, 2022. doi: 10.1016/S0167-8140(22)03288-1
[https://www.thegreenjournal.com/article/S0167-8140\(22\)03288-1/fulltext](https://www.thegreenjournal.com/article/S0167-8140(22)03288-1/fulltext)

9. PO-1363 Detection rate of 68Ga-PSMA PET/CT from a prospective study: PSICHE trial (NCT05022914)
 Francolini G, Di Cataldo V, Detti B, Allegra A, Burchini L, **Cicccone LP**, Cerbai C, Mattioli C, Frosini G, Guerrieri B, Aquilano M, Salvestrini V, Chiti A, Sollini M, Simontacchi G, Desideri I, Livi L.
 Radiotherapy and Oncology, Vol 170, Suppl 1, S1157-S1158, May 01, 2022 doi: 10.1016/S0167-8140(22)03327-8
[https://www.thegreenjournal.com/article/S0167-8140\(22\)03327-8/fulltext](https://www.thegreenjournal.com/article/S0167-8140(22)03327-8/fulltext)

10. Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis.
 Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Gandini S, Corso F, **Cicccone LP**, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Desideri I, D'Angelillo RM, Masi L, Ingrosso G, Di Staso M, Mazzeo E, Trippa F, Lohr F, Bruni A, Livi L.
 Radiol Med. 2022 Apr;127(4):449-457. doi: 10.1007/s11547-022-01465-w.
<https://link.springer.com/article/10.1007/s11547-022-01465-w>

11. Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.
 Francolini G, **Cicccone LP**, Livi L.
 Eur Urol. 2022 Apr;81(4):e98-e99. doi: 10.1016/j.eururo.2021.11.034.
<https://www.sciencedirect.com/science/article/pii/S0302283821022648?via%3Dihub>

12. Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years
 Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Masi L, Doro R, Scoccimarro E, Bellini C, Aquilano M, Allegra AG, Peruzzi A, Guerrieri B, Morelli I, Valzano M, **Cicccone LP**, Salvestrini V, Desideri I, Livi L.
 Clin Oncol (R Coll Radiol). 2022 Jan;34(1):50-56. doi: 10.1016/j.clon.2021.11.002
[https://www.clinicaloncologyonline.net/article/S0936-6555\(21\)00421-0/fulltext](https://www.clinicaloncologyonline.net/article/S0936-6555(21)00421-0/fulltext)

13. PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.
 Francolini G, Loi M, **Cicccone LP**, Mangoni M, Detti B, Di Cataldo V, Aquilano M, Allegra A, Pinzani P, Salvianti F, Cerbai C, Burchini L, Frosini G, Mattioli M, Salvestrini V, Guerrieri B, Salvatore G, Sottili M, Desideri I, Livi L.
 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 137-137. DOI:10.1200/JCO.2022.40.6_suppl.137
https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.137

14. ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.
 Francolini G, Detti B, Di Cataldo V, Caini S, Alitto AR, Parisi S, Demofonti C, Bruni A, Ingrosso G, Timon G, Allegra A, Aquilano M, **Cicccone LP**, Salvestrini, Frosini G, Cerbai C, Desideri I, Meattini I, Mangoni M, Livi L.
 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 100-100. DOI:10.1200/JCO.2022.40.6_suppl.100
https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.100

15. P091 Concomitant immuno-radiotherapy in metastatic renal cell carcinoma: multicenter analysis
 Francolini G, Di Cataldo V, Detti B, Loi M, Ghirardelli P, Vavassori V, Nicosia L, Alongi F, Triggiani L, La Mattina S, Allegra AG, Cerbai C, Aquilano M, Burchini L, Mattioli C, Peruzzi A, Lucidi S, Scoccimarro E, Mariotti M, Salvestrini V, Stocchi G, **Cicccone LP**, Desideri I, Livi L.

16. Correction to: Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility
Desideri I, Francolini G, **Ciccione LP**, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
Support Care Cancer. 2021 Nov 9:1–2. doi: 10.1007/s00520-021-06665-0
<https://link.springer.com/article/10.1007/s00520-021-06665-0>
17. Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis
Francolini G, Bellini C, Di Cataldo V, Detti B, Bruni A, Alicino G, Triggiani L, La Mattina S, D'Angelillo RM, Demofonti C, Mazzola R, Cuccia F, Alongi F, Aquilano M, Allegra AG, **Ciccione LP**, Burchini L, Salvestrini V, Morelli I, Frosini G, Desideri I, Livi L.
Clinical Oncology, 2021, doi: 10.1016/j.clon.2021.09.014
www.sciencedirect.com/science/article/pii/S0936655521003496
18. PO-1087 Hypofractionated radiotherapy for breast cancer orbital lesion: a multicentric series of 35 patients
Desideri I, **Ciccione LP**, Piperno G, Augugliaro M, Jereczek-Fossa BA, Navarra P, Dominici L, Scorsetti M, Salvestrini V, Riva G, Di Cataldo V, Visani L, Loi M, Meattini I, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S904-S906 doi: 10.1016/S0167-8140(21)07538-1
<https://www.sciencedirect.com/science/article/pii/S0167814021075381>
19. PO-0998 Dosimetric predictors of patient-reported taste alteration in head and neck cancer: a cohort study
Scoccimarro E, **Ciccione LP**, Caini S, Aquilano M, Peruzzi A, Becherini C, Livi L, Desideri I, Bonomo P.
Radiotherapy and Oncology, Vol 161, Suppl 1, S830-S831. doi: 10.1016/S0167-8140(21)07449-1
<https://www.sciencedirect.com/science/article/pii/S0167814021074491>
20. PO-1316 Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation
Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Allegra AG, Bellini C, Aquilano M, **Ciccione LP**, Mariotti M, Salvestrini V, Scoccimarro E, Valzano M, Simontacchi G, Bonomo P, Lucidi S, Desideri I, Meattini I, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S1080-S1081. doi: 10.1016/S0167-8140(21)07767-7
<https://www.sciencedirect.com/science/article/pii/S0167814021077677>
21. PD-0849 Concomitant Nivolumab and RT in metastatic kidney cancer. Benefit of ablative vs palliative approach
Francolini G, Di Cataldo V, Detti B, Loi M, Ghirardelli P, Vavassori V, Nicosia L, Alongi F, Triggiani L, La Mattina S, Allegra AG, Scoccimarro E, Aquilano M, Lucidi S, Valzano M, Peruzzi A, Morelli I, Mariotti M, Salvestrini V, Stocchi G, **Ciccione LP**, Desideri I, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S683. doi: 10.1016/S0167-8140(21)07128-0
<https://www.sciencedirect.com/science/article/pii/S0167814021071280>
22. PO-0997 Lack of CTV_P2 is not associated with a detrimental outcome in oropharyngeal cancer: a cohort study
Ciccione LP, Zani M, Scoccimarro E, Aquilano M, Banini M, Caprara L, Mariotti M, Salvestrini V, Becherini C, Desideri I, Marrazzo L, Pallotta S, Livi L, Bonomo P.
Radiotherapy and Oncology, Vol 161, Suppl 1, S829-S830, doi: 10.1016/S0167-8140(21)07448-X
<https://www.sciencedirect.com/science/article/pii/S016781402107448X>
23. PO-1921 Radiosensitizing effect of Trabectedin on human soft tissue sarcoma cells Aquilano M, Salvatore G, Loi M, Greto D, Scoccimarro E, **Ciccione LP**, Stocchi G, Salvestrini V, Santini C, Sottili M, Mangoni M, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S1638-S1639. DOI:10.1016/S0167-8140(21)08372-9
<https://www.sciencedirect.com/science/article/pii/S0167814021083729>
24. PO-1366 Pattern of recurrence after SBRT in prostate cancer patients with nodal pelvic relapse
Francolini G, Bellini C, Di Cataldo V, Detti B, Bruni A, Alicino G, Triggiani L, La Mattina S, D'Angelillo RM, Demofonti C, Mazzola R, Cuccia F, Alongi F, Aquilano M, Allegra AG, **Ciccione LP**, Stocchi G, Salvestrini V, Guerrieri B, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S1120-S1121. DOI:10.1016/S0167-8140(21)07817-8
<https://www.sciencedirect.com/science/article/pii/S0167814021078178?via%3Dihub>

25. May Different Treatment Volumes and Technical Approaches Have an Impact on Second Malignancies Risk?
 Francolini G, **Ciccone LP**, Di Cataldo V, Detti B, Simontacchi G, Loi M, Mangoni M, Desideri I, Meattini I, Livi L.
 J Clin Oncol. 2021 Sep 17; JCO2101790. doi: 10.1200/JCO.21.01790
<https://ascopubs.org/doi/pdf/10.1200/JCO.21.01790>
26. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275)
 Francolini G, Loi M, Salvestrini V, Mangoni M, Detti B, Di Cataldo V, Aquilano M, Pinzani P, Salvianti F, Desideri I, Mariotti M, Garlatti P, Stocchi G, **Ciccone LP**, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L.
 Clin Exp Metastasis. 2021 Aug 19. doi: 10.1007/s10585-021-10118-7.
<https://link.springer.com/article/10.1007/s10585-021-10118-7>
27. Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
 Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, Camerini A, Federici F, Meoni G, Capareello C, Turrini M, Rossi V, **Ciccone LP**, Pecora I, Fantechi B, Antonuzzo L, Giannarelli D, Baldini E.
 Anticancer Agents Med Chem. 2021 Jul 26. doi: 10.2174/1871520621666210727112212.
<https://www.eurekaselect.com/194998/article>
28. Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: a systematic review
 Desideri I, Becherini C, Belgioia L, Merlotti A, **Ciccone LP**, Franzese C, Loi M, De Felice F, Mazzola R, Caini S, Livi L, Bonomo P.
 Oral Oncol. 2021 May 24;119:105355. doi: 10.1016/j.oraloncology.2021.105355.
<https://www.sciencedirect.com/science/article/abs/pii/S1368837521001780?via%3Dihub>
29. Impact of COVID-19 on workload burden of a complex radiotherapy facility.
 Francolini G, Desideri I, Stocchi G, **Ciccone LP**, Salvestrini V, Garlatti P, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
 Radiol Med. 2021 May;126(5):717-721. doi: 10.1007/s11547-021-01338-8.
<https://link.springer.com/article/10.1007/s11547-021-01338-8>
30. ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.
 Francolini G, Garlatti P, Loi M, Detti B, Aquilano M, Allegra A, Guerrieri B, Salvestrini V, Pinzani P, Bellini C, Salvianti F, Stocchi G, **Ciccone LP**, Salvatore G, Sottili M, Di Cataldo V, Desideri I, Mangoni M, Meattini I, Livi L.
 Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021) 118-118. doi: 10.1200/JCO.2021.39.6_suppl.118
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.118
31. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
 Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, **Ciccone LP**, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M.
 Lung Cancer. 2020 Dec; 150:123-131. doi: 10.1016/j.lungcan.2020.10.008.
[https://www.lungcancerjournal.info/article/S0169-5002\(20\)30658-9/fulltext](https://www.lungcancerjournal.info/article/S0169-5002(20)30658-9/fulltext)
32. Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery.
 Scoccianti S, Perna M, Olmetto E, Delli Paoli C, Terziani F, **Ciccone LP**, Detti B, Greto D, Simontacchi G, Grassi R, Scoccimarro E, Bonomo P, Mangoni M, Desideri I, Di Cataldo V, Vernaleone M, Casati M, Pallotta S, Livi L.
 Crit Rev Oncol Hematol. 2020 Nov 28;157:103184. doi: 10.1016/j.critrevonc.2020.103184.
<https://www.sciencedirect.com/science/article/abs/pii/S1040842820303206>
33. 412P Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial.
 Camerini A, Del Conte A, Pezzuto A, Scotti V, Facchinetti F, **Ciccone LP**, Perna M, Sartori G, Puccetti C, Ricci A, Santo A, Tiseo M, Amoroso D.

34. Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing 1 line treatment with abiraterone acetate (ARTO trial-NCT03449719)
Francolini G, Garlatti P, Detti B, Bruni A, Mantini G, Pergolizzi S, Borghetti P, D'Angelillo RM, Alongi F, Jereczek-Fossa BA, Franzese C, Tagliagambe A, Di Cataldo V, Aquilano M, Mariotti M, Salvestrini V, **Ciccione LP**, Stocchi G, Livi L.
European Urology Open Science 21:S150 doi: 10.1016/S2666-1683(20)36207-8
<https://www.sciencedirect.com/science/article/pii/S2666168320362078?via%3Dihub>
35. Comparison Between Accelerated Partial Breast Irradiation and Whole Breast Irradiation: APBI IMRT Florence Retrospective Analysis of Subjective, Objective and Patient- reported Cosmetic Outcomes
Meattini I, **Ciccione LP**, Lucidi S, Desideri I, Visani L, Perna M, Peruzzi A, Scotti V, Simontacchi G, Livi L.
International Journal of Radiation Oncology Biology Physics 108(3) doi: 10.1016/j.ijrobp.
[https://www.redjournal.org/article/S0360-3016\(20\)32326-9/fulltext](https://www.redjournal.org/article/S0360-3016(20)32326-9/fulltext)
36. PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis
Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Masi L, **Ciccione LP**, Bruni A, Ingrosso G, Mazzeo E, Trippa F, Lohr F, Livi L.
Radiotherapy and Oncology 152:S59-S60 doi: 10.1016/S0167-8140(21)00145-6
[https://www.thegreenjournal.com/article/S0167-8140\(21\)00145-6/pdf](https://www.thegreenjournal.com/article/S0167-8140(21)00145-6/pdf)
37. Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy.
Desideri I, Francolini G, **Ciccione LP**, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
Support Care Cancer. 2020 Oct 2:1-7. doi: 10.1007/s00520-020-05793-3
<https://link.springer.com/article/10.1007/s00520-020-05793-3>
38. 617P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275)
Francolini G, Salvestrini V, Loi M, Mangoni M, Detti B, Pinzani P, Salvianti F, Desideri I, Aquilano M, Mariotti M, Garlatti P, Stocchi G, **Ciccione LP**, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L.
Annals of Oncology Volume 31, Supplement 4, S538-S539. doi: 10.1016/j.annonc.2020.08.930
[https://www.annalsofoncology.org/article/S0923-7534\(20\)40926-3/fulltext](https://www.annalsofoncology.org/article/S0923-7534(20)40926-3/fulltext)
39. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, **Ciccione LP**, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M.
Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023.
[https://www.ejancer.com/article/S0959-8049\(20\)30096-4/fulltext](https://www.ejancer.com/article/S0959-8049(20)30096-4/fulltext)
40. Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2- breast cancer (MBC).
Meattini I, Scoccimarro E, Saieva C, Desideri I, Visani L, Dominici L, Cerbai C, Aquilano M, **Ciccione LP**, Palmieri VE, Scotti V, Nori J, Bernini M, Orzalesi L, Sanchez L, Dieci MV, Bianchi S, Livi L.
Journal of Clinical Oncology 38(15_suppl):562-562 doi: 10.1200/JCO.2020.38.15_suppl.562
https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.562
41. Thermal Ablation versus SBRT in liver tumours: pros and cons
Loi M, Desideri I, Dominici L, Francolini G, Garlatti P, **Ciccione LP**, Stocchi G, Salvestrini V, Meattini I, Livi L.
Med Oncol. 2020 Apr 29;37(6):52. doi: 10.1007/s12032-020-01377-7.
<https://link.springer.com/article/10.1007/s12032-020-01377-7>
42. Artificial Intelligence in radiotherapy: state of the art and future directions
Francolini G, Desideri I, Stocchi G, Salvestrini V, **Ciccione LP**, Garlatti P, Loi M, Livi L.

43. Preliminary results of a prospective assessment of androgen receptor splice variants in mCRPC patients undergoing androgen receptor targeted agents.
Francolini G, Loi M, Detti B, Mangoni M, Desideri I, Muntoni C, **Ciccione LP**, Aquilano M, Pinzani P, Salvianti P, Lucidi S, Mariotti M, Garlatti P, Salvatore G, Sottili M, Livi L.
Journal of Clinical Oncology 38(6_suppl):246-246. doi: 10.1200/JCO.2020.38.6_suppl.246
https://ascopubs.org/doi/10.1200/JCO.2020.38.6_suppl.246
44. EP1.04-02 Predictors of Lung Toxicity in First Line Pembrolizumab for Advanced NSCLC: An Interim Analysis of PRELUTOX Study
Bonti V, Teriaca MA, Lavacchi D, Perna M, Caini S, Mazzoni F, Maragna V, Rosi E, Giannelli F, Cozzi D, Visani L, Calabrò A, Bartolucci M, **Ciccione LP**, Mariotti M, Flego N, Comin CE, Pezzulla D, Moroni C, Cavigli E, Bindi A, Caramia G, Meacci F, Miele V, Lavorini F, Voltolini L, Livi L, Scotti V, Ferrari K.
Journal of Thoracic Oncology 14(10):S966-S967 doi: 10.1016/j.jtho.2019.08.2118
[https://www.jto.org/article/S1556-0864\(19\)32801-1/fulltext](https://www.jto.org/article/S1556-0864(19)32801-1/fulltext)
45. Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings.
Bonomo P, Desideri I, Loi M, **Ciccione LP**, Lo Russo M, Becherini C, Greto D, Simontacchi G, Pimpinelli N, Livi L.
Support Care Cancer. 2019 Aug;27(8):2957-2967. doi: 10.1007/s00520-018-4606-2.
<https://link.springer.com/article/10.1007/s00520-018-4606-2>
46. OC-0276 Stereotactic radiosurgery plus immunotherapy or targeted therapy for brain metastases from NSCLC
Olmetto E, Delli Paoli C, **Ciccione LP**, Perna M, Grassi R, Scocciarro E, Scoccianti S, Greto D, Desideri I, Simontacchi G, Marrazzo L, Arilli C, Casati M, Compagnucci A, Pecchioli G, Pallotta S, Livi L.
Radiotherapy and Oncology 133:S136-S137 doi: 10.1016/S0167-8140(19)30696
[https://www.thegreenjournal.com/article/S0167-8140\(19\)30696-6/pdf](https://www.thegreenjournal.com/article/S0167-8140(19)30696-6/pdf)
47. PO-148 Management of bio-radiation dermatitis in HNSCC: emphasizing the role of calcium alginate dressings
Bonomo P, Desideri I, Loi M, **Ciccione LP**, Lo Russo M, Becherini C, Visani L, Salvestrini V, Mariotti M, Pimpinelli N, Livi L.
Radiotherapy and Oncology 132:78-79 doi: 10.1016/S0167-8140(19)30314-7
[https://www.thegreenjournal.com/article/S0167-8140\(19\)30314-7/pdf](https://www.thegreenjournal.com/article/S0167-8140(19)30314-7/pdf)

ALLEGATO 3: AFFILIAZIONI A SOCIETA' SCIENTIFICHE

AIRO (Associazione Italiana Radioterapia Oncologica)

ESTRO (Società Europea di radioterapia Oncologica)

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.

Tale documento ha funzione di autocertificazione ai sensi del D.P.R. n. 445 del 28/12/2000.

Pavia, 07/11/2022

Lucia Pia Ciccione